AATHEN High-level cluster research goal is defined in two points :
-
Identify new Angiotensin Receptor Blocker (ARB)-like small molecules with non-blood pressure-related therapeutic properties (cancer, cardiovascular, pulmonary, neurodegenerative, COVID-19, diabetes, etc).
-
Generate new IP and spin-off companies, improve grant submission competitiveness and facilitate translational collaborations.
With the help of Mitacs and other partners, we have successfully designed and synthesized +30 novel ARB-derived small molecules that no longer block AT1R but have retained at least some of their therapeutic properties. Not only were invention disclosures filed with UILO but unique non-BP related therapeutic blood biomarkers were identified and a spin-off company created (ARbio Therapeutics), supporting the concept that significant technological developments can arise from existing ARBs.